Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations
- PMID: 16902148
- DOI: 10.1182/blood-2006-05-021568
Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations
Abstract
Human intravenous immunoglobulin (IVIg) preparations are increasingly used for the treatment of autoimmune diseases. Earlier work demonstrated the presence of autoantibodies against Fas in IVIg, suggesting that IVIg might be able to induce caspase-dependent cell death in Fas-sensitive cells. In this study, we demonstrate that sialic acid-binding Ig-like lectin 9 (Siglec) represents a surface molecule on neutrophils that is activated by IVIg, resulting in caspase-dependent and caspase-independent forms of cell death. Neutrophil death was mediated by naturally occurring anti-Siglec-9 autoantibodies present in IVIg. Moreover, the efficacy of IVIg-mediated neutrophil killing was enhanced by the proinflammatory cytokines granulocyte/macrophage colony-stimulating factor (GM-CSF) and interferon-gamma (IFN-gamma), and this additional cell death required reactive oxygen species (ROSs) but not caspases. Anti- Siglec-9 autoantibody-depleted IVIg failed to induce this caspase-independent neutrophil death. These findings contribute to our understanding of how IVIg preparations exert their immunoregulatory effects under pathologic conditions and may provide a possible explanation for the neutropenia that is sometimes seen in association with IVIg therapy.
Comment in
-
Autophagic-like cell death in neutrophils induced by autoantibodies.Autophagy. 2007 Jan-Feb;3(1):67-8. doi: 10.4161/auto.3436. Epub 2007 Jan 27. Autophagy. 2007. PMID: 17102587 Review.
Similar articles
-
Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies.J Allergy Clin Immunol. 2007 Apr;119(4):1005-11. doi: 10.1016/j.jaci.2007.01.023. Epub 2007 Mar 2. J Allergy Clin Immunol. 2007. PMID: 17337295
-
Autophagic-like cell death in neutrophils induced by autoantibodies.Autophagy. 2007 Jan-Feb;3(1):67-8. doi: 10.4161/auto.3436. Epub 2007 Jan 27. Autophagy. 2007. PMID: 17102587 Review.
-
Cell death modulation by intravenous immunoglobulin.J Clin Immunol. 2010 May;30 Suppl 1:S24-30. doi: 10.1007/s10875-010-9411-8. J Clin Immunol. 2010. PMID: 20405180 Review.
-
Dimeric IVIG contains natural anti-Siglec-9 autoantibodies and their anti-idiotypes.Allergy. 2011 Aug;66(8):1030-7. doi: 10.1111/j.1398-9995.2011.02579.x. Epub 2011 Mar 9. Allergy. 2011. PMID: 21385183
-
Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment.Blood. 2005 Aug 15;106(4):1423-31. doi: 10.1182/blood-2004-10-4112. Epub 2005 Apr 12. Blood. 2005. PMID: 15827126
Cited by
-
Systems biology and artificial intelligence analysis highlights the pleiotropic effect of IVIg therapy in autoimmune diseases with a predominant role on B cells and complement system.Front Immunol. 2022 Sep 30;13:901872. doi: 10.3389/fimmu.2022.901872. eCollection 2022. Front Immunol. 2022. PMID: 36248801 Free PMC article.
-
Kawasaki Disease: The Role of Immune Complexes Revisited.Front Immunol. 2019 Jun 12;10:1156. doi: 10.3389/fimmu.2019.01156. eCollection 2019. Front Immunol. 2019. PMID: 31263461 Free PMC article. Review.
-
Immune response to intravenous immunoglobulin in patients with Kawasaki disease and MIS-C.J Clin Invest. 2021 Oct 15;131(20):e147076. doi: 10.1172/JCI147076. J Clin Invest. 2021. PMID: 34464357 Free PMC article.
-
The emerging role of autophagy in the pathophysiology of diabetes mellitus.Autophagy. 2011 Jan;7(1):2-11. doi: 10.4161/auto.7.1.13044. Epub 2011 Jan 1. Autophagy. 2011. PMID: 20935516 Free PMC article. Review.
-
Targeted Therapies for Autoimmune Bullous Diseases: Current Status.Drugs. 2018 Oct;78(15):1527-1548. doi: 10.1007/s40265-018-0976-5. Drugs. 2018. PMID: 30238396 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous